BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9278394)

  • 21. [Inhibitory action of E3810 on H+,K(+)-ATPase and gastric acid secretion in vitro].
    Fujisaki H; Oketani K; Shibata H; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Takeguchi N
    Nihon Yakurigaku Zasshi; 1993 Dec; 102(6):389-97. PubMed ID: 8282270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuing development of acid pump inhibitors: site of action of pantoprazole.
    Shin JM; Besancon M; Prinz C; Simon A; Sachs G
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of covalent with reversible inhibitor binding sites of the gastric H,K-ATPase by site-directed mutagenesis.
    Lambrecht N; Munson K; Vagin O; Sachs G
    J Biol Chem; 2000 Feb; 275(6):4041-8. PubMed ID: 10660561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
    Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
    Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of five antisecretory agents acting via gastric H+/K+-ATPase.
    Bastaki SM; Chandranath I; Garner A
    J Physiol Paris; 2000; 94(1):19-23. PubMed ID: 10761684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acid secretion and the H,K ATPase of stomach.
    Prinz C; Kajimura M; Scott D; Helander H; Shin J; Besancon M; Bamberg K; Hersey S; Sachs G
    Yale J Biol Med; 1992; 65(6):577-96. PubMed ID: 1341065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
    Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
    Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
    Tomiyama Y; Morii M; Takeguchi N
    Biochem Pharmacol; 1994 Nov; 48(11):2049-55. PubMed ID: 7802694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
    Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
    Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
    J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological aspects of acid secretion.
    Hirschowitz BI; Keeling D; Lewin M; Okabe S; Parsons M; Sewing K; Wallmark B; Sachs G
    Dig Dis Sci; 1995 Feb; 40(2 Suppl):3S-23S. PubMed ID: 7859583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligomeric regulation of gastric H+,K+-ATPase.
    Morii M; Hayata Y; Mizoguchi K; Takeguchi N
    J Biol Chem; 1996 Feb; 271(8):4068-72. PubMed ID: 8626741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
    Jana K; Bandyopadhyay T; Ganguly B
    J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
    Morii M; Takata H; Fujisaki H; Takeguchi N
    Biochem Pharmacol; 1990 Feb; 39(4):661-7. PubMed ID: 2154989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
    Shin JM; Cho YM; Sachs G
    J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
    Morozov IA
    Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
    Florent C; Forestier S
    Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):195-200. PubMed ID: 9058634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitor and ion binding sites on the gastric H,K-ATPase.
    Munson K; Garcia R; Sachs G
    Biochemistry; 2005 Apr; 44(14):5267-84. PubMed ID: 15807521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.